Rallybio (RLYB) Competitors

$14.08 -0.30 (-2.11%)

As of 01:51 PM Eastern

RLYB vs. PRLD, AMRN, EDIT, LENZ, and ELYM

Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Prelude Therapeutics (PRLD), Amarin (AMRN), Editas Medicine (EDIT), LENZ Therapeutics (LENZ), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry.

How does Rallybio compare to Prelude Therapeutics?

Rallybio (NASDAQ:RLYB) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Rallybio has higher earnings, but lower revenue than Prelude Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	86.58	-$8.98M	-$2.56	N/A
Prelude Therapeutics	$12.14M	25.30	-$99.50M	-$1.29	N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rallybio has a beta of -1.1, indicating that its share price is 210% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

Prelude Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -1,046.39%. Rallybio's return on equity of -56.93% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-1,046.39%	-56.93%	-52.67%
Prelude Therapeutics	N/A	-129.98%	-80.85%

Prelude Therapeutics has a consensus price target of $7.67, indicating a potential upside of 57.23%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Rallybio had 5 more articles in the media than Prelude Therapeutics. MarketBeat recorded 8 mentions for Rallybio and 3 mentions for Prelude Therapeutics. Rallybio's average media sentiment score of 1.33 beat Prelude Therapeutics' score of 0.52 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prelude Therapeutics beats Rallybio on 9 of the 16 factors compared between the two stocks.

How does Rallybio compare to Amarin?

Rallybio (NASDAQ:RLYB) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

In the previous week, Rallybio had 8 more articles in the media than Amarin. MarketBeat recorded 8 mentions for Rallybio and 0 mentions for Amarin. Rallybio's average media sentiment score of 1.33 beat Amarin's score of 0.00 indicating that Rallybio is being referred to more favorably in the media.

Company	Overall Sentiment
Rallybio	Positive
Amarin	Neutral

Amarin has a consensus price target of $12.00, suggesting a potential downside of 20.74%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Rallybio has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	86.58	-$8.98M	-$2.56	N/A
Amarin	$213.65M	1.47	-$38.80M	-$0.65	N/A

Rallybio has a beta of -1.1, indicating that its share price is 210% less volatile than the S&P 500. Comparatively, Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amarin has a net margin of -15.51% compared to Rallybio's net margin of -1,046.39%. Amarin's return on equity of -2.99% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-1,046.39%	-56.93%	-52.67%
Amarin	-15.51%	-2.99%	-2.07%

Summary

Amarin beats Rallybio on 9 of the 16 factors compared between the two stocks.

How does Rallybio compare to Editas Medicine?

Rallybio (NASDAQ:RLYB) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Rallybio has a beta of -1.1, indicating that its share price is 210% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500.

Editas Medicine has a net margin of -281.59% compared to Rallybio's net margin of -1,046.39%. Rallybio's return on equity of -56.93% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-1,046.39%	-56.93%	-52.67%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, Editas Medicine had 7 more articles in the media than Rallybio. MarketBeat recorded 15 mentions for Editas Medicine and 8 mentions for Rallybio. Rallybio's average media sentiment score of 1.33 beat Editas Medicine's score of 0.12 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

Rallybio has higher earnings, but lower revenue than Editas Medicine. Rallybio is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	86.58	-$8.98M	-$2.56	N/A
Editas Medicine	$38.69M	7.91	-$160.06M	-$1.23	N/A

Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 72.80%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 2.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Editas Medicine beats Rallybio on 9 of the 16 factors compared between the two stocks.

How does Rallybio compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

LENZ Therapeutics currently has a consensus target price of $44.00, suggesting a potential upside of 342.88%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LENZ Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.1, indicating that its stock price is 210% less volatile than the S&P 500.

LENZ Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -1,046.39%. LENZ Therapeutics' return on equity of -37.47% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-37.47%	-35.13%
Rallybio	-1,046.39%	-56.93%	-52.67%

In the previous week, Rallybio had 6 more articles in the media than LENZ Therapeutics. MarketBeat recorded 8 mentions for Rallybio and 2 mentions for LENZ Therapeutics. Rallybio's average media sentiment score of 1.33 beat LENZ Therapeutics' score of 0.90 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rallybio has lower revenue, but higher earnings than LENZ Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	16.32	-$82.13M	-$2.81	N/A
Rallybio	$860K	86.58	-$8.98M	-$2.56	N/A

Summary

LENZ Therapeutics beats Rallybio on 9 of the 16 factors compared between the two stocks.

How does Rallybio compare to Eliem Therapeutics?

Rallybio (NASDAQ:RLYB) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Rallybio had 8 more articles in the media than Eliem Therapeutics. MarketBeat recorded 8 mentions for Rallybio and 0 mentions for Eliem Therapeutics. Rallybio's average media sentiment score of 1.33 beat Eliem Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the media.

Company	Overall Sentiment
Rallybio	Positive
Eliem Therapeutics	Neutral

Rallybio has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	86.58	-$8.98M	-$2.56	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Rallybio has a beta of -1.1, indicating that its stock price is 210% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500.

Eliem Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -1,046.39%. Eliem Therapeutics' return on equity of -47.03% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-1,046.39%	-56.93%	-52.67%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Summary

Rallybio beats Eliem Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLYB vs. The Competition

Export

Metric	Rallybio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$74.46M	$3.38B	$6.20B	$12.30B
Dividend Yield	N/A	2.25%	2.78%	5.22%
P/E Ratio	-5.50	15.23	20.68	25.76
Price / Sales	86.58	309.83	558.03	78.11
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	1.28	7.01	9.82	6.78
Net Income	-$8.98M	$24.11M	$3.55B	$333.43M
7 Day Performance	N/A	N/A	N/A	0.49%
1 Month Performance	66.78%	5.52%	6.72%	9.25%
1 Year Performance	500.51%	80.06%	42.70%	43.00%

Rallybio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLYB Rallybio	0.8891 of 5 stars	$14.08 -2.1%	N/A	+513.5%	$74.46M	$860K	N/A	40	Positive News Upcoming Earnings Analyst Forecast Gap Up
PRLD Prelude Therapeutics	4.1639 of 5 stars	$4.67 -1.5%	$7.67 +64.2%	+522.3%	$298.63M	$12.14M	N/A	120	Upcoming Earnings
AMRN Amarin	0.9061 of 5 stars	$14.50 +1.8%	$12.00 -17.2%	+44.6%	$296.25M	$213.65M	N/A	360
EDIT Editas Medicine	3.476 of 5 stars	$3.04 +1.3%	$5.40 +77.6%	+114.5%	$293.72M	$40.52M	N/A	230	Earnings Report Analyst Downgrade
LENZ LENZ Therapeutics	2.561 of 5 stars	$9.07 -2.3%	$44.00 +385.1%	-61.8%	$290.97M	$19.09M	N/A	110	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLYB) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rallybio (RLYB) Competitors

RLYB vs. PRLD, AMRN, EDIT, LENZ, and ELYM

How does Rallybio compare to Prelude Therapeutics?

Summary

How does Rallybio compare to Amarin?

Summary

How does Rallybio compare to Editas Medicine?

Summary

How does Rallybio compare to LENZ Therapeutics?

Summary

How does Rallybio compare to Eliem Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rallybio (RLYB) Competitors

RLYB vs. PRLD, AMRN, EDIT, LENZ, and ELYM

How does Rallybio compare to Prelude Therapeutics?

Which has better valuation & earnings, RLYB or PRLD?

Do institutionals & insiders have more ownership in RLYB or PRLD?

Which has more volatility & risk, RLYB or PRLD?

Is RLYB or PRLD more profitable?

Do analysts recommend RLYB or PRLD?

Does the media favor RLYB or PRLD?

Summary

How does Rallybio compare to Amarin?

Does the media prefer RLYB or AMRN?

Do analysts rate RLYB or AMRN?

Which has higher earnings & valuation, RLYB or AMRN?

Which has more volatility & risk, RLYB or AMRN?

Do institutionals and insiders have more ownership in RLYB or AMRN?

Is RLYB or AMRN more profitable?

Summary

How does Rallybio compare to Editas Medicine?

Which has more volatility & risk, RLYB or EDIT?

Is RLYB or EDIT more profitable?

Does the media favor RLYB or EDIT?

Which has better valuation & earnings, RLYB or EDIT?

Do analysts prefer RLYB or EDIT?

Do insiders & institutionals hold more shares of RLYB or EDIT?

Summary

How does Rallybio compare to LENZ Therapeutics?

Do analysts prefer LENZ or RLYB?

Do institutionals & insiders hold more shares of LENZ or RLYB?

Which has more risk & volatility, LENZ or RLYB?

Is LENZ or RLYB more profitable?

Does the media refer more to LENZ or RLYB?

Which has preferable valuation and earnings, LENZ or RLYB?

Summary

How does Rallybio compare to Eliem Therapeutics?

Do institutionals and insiders believe in RLYB or ELYM?

Do analysts prefer RLYB or ELYM?

Does the media prefer RLYB or ELYM?

Which has better earnings and valuation, RLYB or ELYM?

Which has more volatility and risk, RLYB or ELYM?

Is RLYB or ELYM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools